I can understand why many investors may be skeptical of Alnylam Pharmaceuticals (NASDAQ:ALNY).
With a $10 billion market cap (as of last night's close), I believe
this is the most highly-valued biotech without an actual approved drug.
That creates considerable downside risk when (and I do believe it's
"when", not "if") a clinical disappointment occurs.
The thing is,
though, that Alnylam continues to make its case stronger and stronger.
Not only has the company been very active in filling out a robust
clinical pipeline, but the incremental data from those drugs has also
been quite strong. Alnylam's latest announcement, positive 12-month data
from an open-label extension study of patisiran, only serves to
highlight that this biotech may in fact be developing a collection of
medicines that deliver clear and significant benefits in a variety of
undertreated conditions.
Read the full article here:
Alnylam Strengthens Its Clinical Case Once Again
No comments:
Post a Comment